english.prescrire.org > Spotlight > 100 most recent > Tirzepatide in heart failure in adults with obesity

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Tirzepatide in heart failure in adults with obesity

 Marketing Authorisations  The dual GLP-1 and GIP agonist tirzepatide is authorised in the European Union by subcutaneous injection for use in certain adults with type 2 diabetes, and in certain patients with obesity or overweight. Here, we examine the published results of a double-blind randomised placebo-controlled trial of tirzepatide in 731 adults with obesity and heart failure with preserved ejection fraction.
Full article available for download by subscribers

 ©Prescrire 1 June 2025

Source: "Tirzepatide in heart failure in adults with obesity" Prescrire Int 2025; 34 (271): 156-157. Subscribers only.

Filet

Enjoy full access to Prescrire International, and support independent information

 
Share
Share on Facebook  
 
 
See also:

"Tirzepatide (Mounjaro°)
in type 2 diabetes.
No better than a GLP-1 agonist"
Prescrire Int 2024;
33 (264): 257-259.
Subscribers only

"Tirzepatide in obesity: not shown 
to represent a therapeutic advance
over semaglutide as of mid-2024"
Prescrire Int 2024;
33 (264): 272.
Subscribers only